title: The role of recombinant human erythropoietin in the management of anaemic cancer patients: focus on haematological malignancies.
abstract: Anaemia, manifesting as fatigue, dizziness, dyspnoea and anorexia, is common among patients with cancer. A host of factors, such as neoplastic bone marrow infiltration, impaired haematopoiesis, autoimmune haemolysis, impaired endogenous erthropoietin production and treatment with cytotoxic agents contribute to the underlying pathology. Traditionally, blood transfusions have formed the mainstay of therapy for the treatment of cancer-related anaemia. Numerous clinical trials have subsequently confirmed the safety and therapeutic utility of recombinant human erythropoietin (rHuEPO) in anaemic cancer patients, including those with haematological malignancies, such as multiple myeloma and non-Hodgkin's lymphoma. Indeed, well over 50% of unselected patients treated with rHuEPO can be expected to respond with increases in haemoglobin level and/or elimination of transfusion need. In addition, a low baseline serum erythropoietin level can identify those patients with haematological malignancies having a very high likelihood of responding to rHuEPO therapy. These findings, in combination with the possibility of titrating to a lower, maintenance dose, have improved the cost-benefit relationship and thus support the use of rHuEPO as an appropriate alternative to blood transfusions for the management of anaemic patients with lymphoma and myeloma.
authors.affiliation: Department of Haematology and Oncology, Karolinska Hospital, Stockholm, Sweden. anders.osterborg@ks.se
authors.forename: A
authors.initials: A
authors.lastname: Osterbor
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000503:physiopathology*; D001803:Blood Transfusion; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000150:complications*; D008223:Lymphoma / Q000150:complications*; D009101:Multiple Myeloma / Q000150:complications*; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin